By the Top Tier Newswire AI Desk · August 20, 2026 at 12:01 PM ET · reviewed against 3 wire stories
REPLIGEN CORP (RGEN) is up +6.63% in the latest session. Our newswire has captured 3 stories on RGEN across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 68/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
RGEN stock surged 6.63% to $188.06 in intraday trade, driven by positive developments tied to Moderna’s Phase 3 trial for melanoma therapy. The biotech sector experienced renewed momentum as analysts highlighted potential benefits for Repligen from the trial results. The stock opened with a 1.4% gap up and reached a session high of $188.73 before settling near $188.46.
What Happened
Repligen’s stock price climbed following analyst commentary that positioned the company as a key beneficiary of Moderna’s recent clinical trial data. Stifel and Wells Fargo both cited the potential for Repligen to gain from the progress in cancer vaccine development. Additionally, price targets from Wells Fargo and J.P. Morgan were raised, with Wells Fargo setting a target of $185 and J.P. Morgan at $175. These adjustments came amid broader biotech sector optimism, with Amgen also reporting strong Q2 results. The stock’s move reflects investor anticipation of continued momentum from favorable developments in the oncology space.
What The Data Shows
The stock’s intraday performance showed a volatile session, with a low of $173.13 and a high of $188.73. Trading volume reached 0.5 million shares, which is 0.4 times the 3-month daily average. The stock hit a fresh 52-week high on August 20, 2026. Over the past 30 days, sentiment has improved, rising from an average of 62 to 68. Recent insider transactions included two sales by the CFO, totaling $186,000. No insider purchases were reported in the last 90 days.
What To Watch
Investors should monitor the company’s next earnings report if scheduled. Otherwise, continued analyst coverage and broader market sentiment toward biotech stocks will be key factors to watch.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RGEN · Aug 20 session (5-min) · +2.23% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 3 stories · 68/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
24d agoStocktwits NewsBULLISH 67Earnings
These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains?
Both Amgen and Repligen saw price target hikes after better-than-expected Q2 results and potential gains from Moderna’s successful Phase 3 trial for melanoma therapy, respectively.
24d agoThe FlyBULLISH 63Analyst
Stifel sees Moderna data as positive for Repligen, Maravai
25d agoThe FlyBULLISH 73Product/PR
Wells sees Repligen among key beneficiaries of Moderna’s cancer vaccine data
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →